Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
8.00    -0.40 (-4.76%)
Bid:
7.50
Ask:
8.50
Spread: 1.00 (13.333%)
Market Cap: £506.60m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Total Voting Rights

30 Jul 2009 07:00

RNS Number : 5134W
Allergy Therapeutics PLC
30 July 2009
 



Thursday 30 July 2009

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Total Voting Rights 

 

 

 

Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that the Company's share capital consists of 276,498,551 Ordinary 0.1p shares with voting rights attached (one vote per Ordinary share). The Company has no shares in Treasury therefore the total number of voting rights in Allergy Therapeutics is 276,498,551. 

 

The above total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Allergy Therapeutics under the FSA's Disclosure and Transparency Rules. 

 

For further information

Allergy Therapeutics

+44 (0) 1903 845 820

Keith Carter, Chief Executive

www.allergytherapeutics.com

Nomura Code Securities

+44 (0) 207 776 1200

Juliet Thompson/ Clare Terlouw

Financial Dynamics

+44 (0) 207 831 3113

Ben BrewertonSusan Quigley

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVREALXNASPNEFE
Date   Source Headline
5th Feb 20073:04 pmRNSHolding(s) in Company
31st Jan 200710:18 amRNSTotal Voting Rights
31st Jan 20077:01 amRNSResearch Update
26th Jan 200710:00 amRNSOpening of Facilities
23rd Jan 20077:01 amRNSResearch Update
15th Jan 20077:00 amRNSNotice of Results
12th Dec 200611:59 amRNSHolding(s) in Company
11th Dec 20063:45 pmRNSHolding(s) in Company
7th Dec 20063:12 pmRNSDirector/PDMR Shareholding
7th Dec 20067:02 amRNSResearch Update
5th Dec 20062:30 pmRNSTotal Voting Rights
6th Nov 200612:12 pmRNSDirector/PDMR Shareholding
3rd Nov 20069:20 amRNSResult of AGM
2nd Nov 200611:39 amRNSDirector/PDMR Shareholding
27th Oct 200610:58 amRNSDirector/PDMR Shareholding
11th Oct 20067:00 amRNSClinical Trials
12th Sep 20067:04 amRNSFinal Results
19th Jul 20067:01 amRNSClinical update
14th Jul 20067:01 amRNSTrading Statement
7th Jul 20064:17 pmRNSDirector/PDMR Shareholding
4th Jul 20067:00 amRNSClinical update
3rd Jul 20064:08 pmRNSHolding(s) in Company
21st Jun 20067:00 amRNSClinical update
11th May 20067:02 amRNSApproval of Vaccine patent
10th May 20063:43 pmRNSDirector/PDMR Shareholding
8th May 200611:44 amRNSHolding(s) in Company
4th May 200612:06 pmRNSEGM Statement
10th Apr 20067:02 amRNSIssue of Equity
28th Mar 20064:28 pmRNSHolding(s) in Company
27th Mar 20067:01 amRNSInterim Results
24th Mar 20067:02 amRNSClinical update
16th Mar 20069:29 amRNSNotice of Results-Amendment
6th Mar 20067:03 amRNSClinical update
1st Mar 20069:30 amRNSNotice of Results
27th Feb 20061:02 pmRNSHolding(s) in Company
9th Jan 20063:32 pmRNSHolding(s) in Company
15th Dec 20057:01 amRNSDirector/PDMR Shareholding
6th Dec 20054:17 pmRNSHolding(s) in Company
2nd Dec 20057:01 amRNSClinical update
22nd Nov 20057:03 amRNSDirectorate change and update
17th Nov 20051:08 pmRNSHolding(s) in Company
14th Nov 20057:01 amRNSChange of Adviser
7th Nov 20057:00 amRNSDirectorate Change
4th Nov 20053:05 pmRNSResult of AGM
25th Oct 20052:27 pmRNSDirector/PDMR Shareholding
13th Sep 20057:01 amRNSFinal Results
24th Aug 20057:00 amRNSChange of Adviser
18th Jul 20057:01 amRNSTrading Statement
11th May 20057:00 amRNSHolding(s) in Company
10th May 20057:01 amRNSClearance for vaccine studies

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.